Exelixis, Inc. (EXEL) Stock Competitors & Peer Comparison
See (EXEL) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EXEL | $50.45 | -1.94% | 12.7B | 16.72 | $3.02 | N/A |
| NVO | $44.17 | -2.94% | 202.5B | 10.67 | $4.27 | +3.94% |
| VRTX | $436.92 | -2.47% | 113.6B | 26.57 | $16.84 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $600.80 | -3.33% | 63.3B | 15.02 | $40.93 | +0.59% |
| ARGX | $834.85 | -0.43% | 51.7B | 36.38 | $22.98 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $299.00 | -1.99% | 40.3B | 76.06 | $3.97 | N/A |
| RVMD | $165.41 | +6.97% | 33.5B | -22.15 | -$7.11 | N/A |
| BNTX | $91.82 | -1.73% | 24.3B | -16.26 | -$5.90 | N/A |
Stock Comparison
EXEL vs NVO Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, NVO has a market cap of 202.5B. Regarding current trading prices, EXEL is priced at $50.45, while NVO trades at $44.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas NVO's P/E ratio is 10.67. In terms of profitability, EXEL's ROE is +0.40%, compared to NVO's ROE of +0.66%. Regarding short-term risk, EXEL is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check NVO's competition here
EXEL vs VRTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, VRTX has a market cap of 113.6B. Regarding current trading prices, EXEL is priced at $50.45, while VRTX trades at $436.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas VRTX's P/E ratio is 26.57. In terms of profitability, EXEL's ROE is +0.40%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, EXEL is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check VRTX's competition here
EXEL vs VRNA Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, EXEL is priced at $50.45, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas VRNA's P/E ratio is -102.80. In terms of profitability, EXEL's ROE is +0.40%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, EXEL is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check VRNA's competition here
EXEL vs REGN Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, REGN has a market cap of 63.3B. Regarding current trading prices, EXEL is priced at $50.45, while REGN trades at $600.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas REGN's P/E ratio is 15.02. In terms of profitability, EXEL's ROE is +0.40%, compared to REGN's ROE of +0.14%. Regarding short-term risk, EXEL is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check REGN's competition here
EXEL vs ARGX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ARGX has a market cap of 51.7B. Regarding current trading prices, EXEL is priced at $50.45, while ARGX trades at $834.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ARGX's P/E ratio is 36.38. In terms of profitability, EXEL's ROE is +0.40%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, EXEL is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check ARGX's competition here
EXEL vs SGEN Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, EXEL is priced at $50.45, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas SGEN's P/E ratio is -57.19. In terms of profitability, EXEL's ROE is +0.40%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, EXEL is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check SGEN's competition here
EXEL vs ALNY Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ALNY has a market cap of 40.3B. Regarding current trading prices, EXEL is priced at $50.45, while ALNY trades at $299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ALNY's P/E ratio is 76.06. In terms of profitability, EXEL's ROE is +0.40%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, EXEL is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check ALNY's competition here
EXEL vs RVMD Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, RVMD has a market cap of 33.5B. Regarding current trading prices, EXEL is priced at $50.45, while RVMD trades at $165.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas RVMD's P/E ratio is -22.15. In terms of profitability, EXEL's ROE is +0.40%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, EXEL is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check RVMD's competition here
EXEL vs BNTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, EXEL is priced at $50.45, while BNTX trades at $91.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas BNTX's P/E ratio is -16.26. In terms of profitability, EXEL's ROE is +0.40%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, EXEL is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check BNTX's competition here
EXEL vs RPRX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, RPRX has a market cap of 24B. Regarding current trading prices, EXEL is priced at $50.45, while RPRX trades at $55.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas RPRX's P/E ratio is 29.35. In terms of profitability, EXEL's ROE is +0.40%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, EXEL is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check RPRX's competition here
EXEL vs UTHR Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, UTHR has a market cap of 23.6B. Regarding current trading prices, EXEL is priced at $50.45, while UTHR trades at $545.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas UTHR's P/E ratio is 20.59. In terms of profitability, EXEL's ROE is +0.40%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, EXEL is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check UTHR's competition here
EXEL vs INSM Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, INSM has a market cap of 23.2B. Regarding current trading prices, EXEL is priced at $50.45, while INSM trades at $105.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas INSM's P/E ratio is -18.57. In terms of profitability, EXEL's ROE is +0.40%, compared to INSM's ROE of -1.30%. Regarding short-term risk, EXEL is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check INSM's competition here
EXEL vs ROIV Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ROIV has a market cap of 21.6B. Regarding current trading prices, EXEL is priced at $50.45, while ROIV trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ROIV's P/E ratio is -55.57. In terms of profitability, EXEL's ROE is +0.40%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, EXEL is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check ROIV's competition here
EXEL vs BGNE Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, EXEL is priced at $50.45, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas BGNE's P/E ratio is -22.55. In terms of profitability, EXEL's ROE is +0.40%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, EXEL is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check BGNE's competition here
EXEL vs INCY Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, INCY has a market cap of 19.3B. Regarding current trading prices, EXEL is priced at $50.45, while INCY trades at $95.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas INCY's P/E ratio is 13.66. In terms of profitability, EXEL's ROE is +0.40%, compared to INCY's ROE of +0.29%. Regarding short-term risk, EXEL is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check INCY's competition here
EXEL vs DNA-WT Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, EXEL is priced at $50.45, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, EXEL's ROE is +0.40%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, EXEL is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check DNA-WT's competition here
EXEL vs MRNA Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, MRNA has a market cap of 18.7B. Regarding current trading prices, EXEL is priced at $50.45, while MRNA trades at $46.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas MRNA's P/E ratio is -5.79. In terms of profitability, EXEL's ROE is +0.40%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, EXEL is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check MRNA's competition here
EXEL vs GMAB Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, GMAB has a market cap of 16.2B. Regarding current trading prices, EXEL is priced at $50.45, while GMAB trades at $25.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas GMAB's P/E ratio is 20.10. In terms of profitability, EXEL's ROE is +0.40%, compared to GMAB's ROE of +0.21%. Regarding short-term risk, EXEL is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check GMAB's competition here
EXEL vs NBIX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, NBIX has a market cap of 15.9B. Regarding current trading prices, EXEL is priced at $50.45, while NBIX trades at $160.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas NBIX's P/E ratio is 24.35. In terms of profitability, EXEL's ROE is +0.40%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, EXEL is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check NBIX's competition here
EXEL vs JAZZ Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, JAZZ has a market cap of 14.8B. Regarding current trading prices, EXEL is priced at $50.45, while JAZZ trades at $231.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas JAZZ's P/E ratio is 1970.75. In terms of profitability, EXEL's ROE is +0.40%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, EXEL is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check JAZZ's competition here
EXEL vs ASND Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ASND has a market cap of 13.8B. Regarding current trading prices, EXEL is priced at $50.45, while ASND trades at $221.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ASND's P/E ratio is 25.18. In terms of profitability, EXEL's ROE is +0.40%, compared to ASND's ROE of -56.42%. Regarding short-term risk, EXEL is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check ASND's competition here
EXEL vs SMMT Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, SMMT has a market cap of 13.6B. Regarding current trading prices, EXEL is priced at $50.45, while SMMT trades at $15.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas SMMT's P/E ratio is -11.03. In terms of profitability, EXEL's ROE is +0.40%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, EXEL is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check SMMT's competition here
EXEL vs BBIO Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, EXEL is priced at $50.45, while BBIO trades at $65.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas BBIO's P/E ratio is -17.72. In terms of profitability, EXEL's ROE is +0.40%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, EXEL is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check BBIO's competition here
EXEL vs IONS Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, IONS has a market cap of 12.6B. Regarding current trading prices, EXEL is priced at $50.45, while IONS trades at $75.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas IONS's P/E ratio is -38.06. In terms of profitability, EXEL's ROE is +0.40%, compared to IONS's ROE of -0.59%. Regarding short-term risk, EXEL is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check IONS's competition here
EXEL vs KRTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, EXEL is priced at $50.45, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas KRTX's P/E ratio is -28.09. In terms of profitability, EXEL's ROE is +0.40%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, EXEL is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check KRTX's competition here
EXEL vs AXSM Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, AXSM has a market cap of 12.1B. Regarding current trading prices, EXEL is priced at $50.45, while AXSM trades at $232.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas AXSM's P/E ratio is -62.86. In terms of profitability, EXEL's ROE is +0.40%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, EXEL is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check AXSM's competition here
EXEL vs MDGL Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, EXEL is priced at $50.45, while MDGL trades at $486.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas MDGL's P/E ratio is -36.77. In terms of profitability, EXEL's ROE is +0.40%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, EXEL is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check MDGL's competition here
EXEL vs RNAM Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, EXEL is priced at $50.45, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas RNAM's P/E ratio is -17.39. In terms of profitability, EXEL's ROE is +0.40%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, EXEL is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check RNAM's competition here
EXEL vs BMRN Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, EXEL is priced at $50.45, while BMRN trades at $55.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas BMRN's P/E ratio is 41.22. In terms of profitability, EXEL's ROE is +0.40%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, EXEL is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check BMRN's competition here
EXEL vs ARWR Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ARWR has a market cap of 11B. Regarding current trading prices, EXEL is priced at $50.45, while ARWR trades at $75.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ARWR's P/E ratio is -34.32. In terms of profitability, EXEL's ROE is +0.40%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, EXEL is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check ARWR's competition here
EXEL vs RXDX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, EXEL is priced at $50.45, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas RXDX's P/E ratio is -56.47. In terms of profitability, EXEL's ROE is +0.40%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check RXDX's competition here
EXEL vs CYTK Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, EXEL is priced at $50.45, while CYTK trades at $73.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CYTK's P/E ratio is -11.21. In terms of profitability, EXEL's ROE is +0.40%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, EXEL is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check CYTK's competition here
EXEL vs KRYS Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, EXEL is priced at $50.45, while KRYS trades at $307.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas KRYS's P/E ratio is 41.31. In terms of profitability, EXEL's ROE is +0.40%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, EXEL is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check KRYS's competition here
EXEL vs IMGN Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, EXEL is priced at $50.45, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas IMGN's P/E ratio is -111.55. In terms of profitability, EXEL's ROE is +0.40%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, EXEL is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check IMGN's competition here
EXEL vs ABVX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, EXEL is priced at $50.45, while ABVX trades at $130.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ABVX's P/E ratio is -24.74. In terms of profitability, EXEL's ROE is +0.40%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, EXEL is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check ABVX's competition here
EXEL vs BPMC Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, EXEL is priced at $50.45, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas BPMC's P/E ratio is -51.58. In terms of profitability, EXEL's ROE is +0.40%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, EXEL is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check BPMC's competition here
EXEL vs CERE Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, EXEL is priced at $50.45, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CERE's P/E ratio is -16.47. In terms of profitability, EXEL's ROE is +0.40%, compared to CERE's ROE of -0.72%. Regarding short-term risk, EXEL is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check CERE's competition here
EXEL vs NUVL Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, NUVL has a market cap of 8.1B. Regarding current trading prices, EXEL is priced at $50.45, while NUVL trades at $96.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas NUVL's P/E ratio is -18.22. In terms of profitability, EXEL's ROE is +0.40%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, EXEL is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check NUVL's competition here
EXEL vs TECH Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, TECH has a market cap of 8.1B. Regarding current trading prices, EXEL is priced at $50.45, while TECH trades at $50.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas TECH's P/E ratio is 73.83. In terms of profitability, EXEL's ROE is +0.40%, compared to TECH's ROE of +0.05%. Regarding short-term risk, EXEL is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check TECH's competition here
EXEL vs HALO Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, EXEL is priced at $50.45, while HALO trades at $67.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas HALO's P/E ratio is 23.35. In terms of profitability, EXEL's ROE is +0.40%, compared to HALO's ROE of +1.26%. Regarding short-term risk, EXEL is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check HALO's competition here
EXEL vs IBRX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, IBRX has a market cap of 7.9B. Regarding current trading prices, EXEL is priced at $50.45, while IBRX trades at $7.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas IBRX's P/E ratio is -8.85. In terms of profitability, EXEL's ROE is +0.40%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, EXEL is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check IBRX's competition here
EXEL vs CORT Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CORT has a market cap of 7.5B. Regarding current trading prices, EXEL is priced at $50.45, while CORT trades at $70.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CORT's P/E ratio is 198.54. In terms of profitability, EXEL's ROE is +0.40%, compared to CORT's ROE of +0.08%. Regarding short-term risk, EXEL is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check CORT's competition here
EXEL vs MTSR Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, EXEL is priced at $50.45, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas MTSR's P/E ratio is -23.58. In terms of profitability, EXEL's ROE is +0.40%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, EXEL is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check MTSR's competition here
EXEL vs PCVX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, PCVX has a market cap of 7.4B. Regarding current trading prices, EXEL is priced at $50.45, while PCVX trades at $48.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas PCVX's P/E ratio is -7.46. In terms of profitability, EXEL's ROE is +0.40%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, EXEL is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check PCVX's competition here
EXEL vs PRAX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, PRAX has a market cap of 7.4B. Regarding current trading prices, EXEL is priced at $50.45, while PRAX trades at $339.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas PRAX's P/E ratio is -26.14. In terms of profitability, EXEL's ROE is +0.40%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, EXEL is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check PRAX's competition here
EXEL vs ALKS Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ALKS has a market cap of 7B. Regarding current trading prices, EXEL is priced at $50.45, while ALKS trades at $42.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ALKS's P/E ratio is 46.88. In terms of profitability, EXEL's ROE is +0.40%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, EXEL is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check ALKS's competition here
EXEL vs IMVT Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, IMVT has a market cap of 6.8B. Regarding current trading prices, EXEL is priced at $50.45, while IMVT trades at $33.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas IMVT's P/E ratio is -12.03. In terms of profitability, EXEL's ROE is +0.40%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, EXEL is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check IMVT's competition here
EXEL vs MRUS Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, EXEL is priced at $50.45, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas MRUS's P/E ratio is -17.05. In terms of profitability, EXEL's ROE is +0.40%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, EXEL is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check MRUS's competition here
EXEL vs ACLX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, EXEL is priced at $50.45, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ACLX's P/E ratio is -28.27. In terms of profitability, EXEL's ROE is +0.40%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, EXEL is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check ACLX's competition here
EXEL vs KYMR Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, KYMR has a market cap of 6.7B. Regarding current trading prices, EXEL is priced at $50.45, while KYMR trades at $79.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas KYMR's P/E ratio is -22.74. In terms of profitability, EXEL's ROE is +0.40%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, EXEL is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check KYMR's competition here
EXEL vs RETA Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, EXEL is priced at $50.45, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas RETA's P/E ratio is -66.29. In terms of profitability, EXEL's ROE is +0.40%, compared to RETA's ROE of +0.47%. Regarding short-term risk, EXEL is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check RETA's competition here
EXEL vs CELC Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CELC has a market cap of 6.5B. Regarding current trading prices, EXEL is priced at $50.45, while CELC trades at $125.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CELC's P/E ratio is -34.07. In terms of profitability, EXEL's ROE is +0.40%, compared to CELC's ROE of -2.45%. Regarding short-term risk, EXEL is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check CELC's competition here
EXEL vs PTGX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, PTGX has a market cap of 6.4B. Regarding current trading prices, EXEL is priced at $50.45, while PTGX trades at $93.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas PTGX's P/E ratio is -55.01. In terms of profitability, EXEL's ROE is +0.40%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, EXEL is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check PTGX's competition here
EXEL vs CNTA Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, EXEL is priced at $50.45, while CNTA trades at $39.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CNTA's P/E ratio is -22.33. In terms of profitability, EXEL's ROE is +0.40%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, EXEL is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check CNTA's competition here
EXEL vs PTCT Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, EXEL is priced at $50.45, while PTCT trades at $73.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas PTCT's P/E ratio is -29.07. In terms of profitability, EXEL's ROE is +0.40%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, EXEL is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check PTCT's competition here
EXEL vs RYTM Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, EXEL is priced at $50.45, while RYTM trades at $87.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas RYTM's P/E ratio is -28.22. In terms of profitability, EXEL's ROE is +0.40%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, EXEL is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check RYTM's competition here
EXEL vs COGT Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, COGT has a market cap of 6B. Regarding current trading prices, EXEL is priced at $50.45, while COGT trades at $35.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas COGT's P/E ratio is -16.11. In terms of profitability, EXEL's ROE is +0.40%, compared to COGT's ROE of -0.83%. Regarding short-term risk, EXEL is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check COGT's competition here
EXEL vs SRRK Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, EXEL is priced at $50.45, while SRRK trades at $48.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas SRRK's P/E ratio is -14.29. In terms of profitability, EXEL's ROE is +0.40%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, EXEL is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check SRRK's competition here
EXEL vs BLTE Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, BLTE has a market cap of 5.8B. Regarding current trading prices, EXEL is priced at $50.45, while BLTE trades at $147.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas BLTE's P/E ratio is -57.15. In terms of profitability, EXEL's ROE is +0.40%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, EXEL is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check BLTE's competition here
EXEL vs TGTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, TGTX has a market cap of 5.8B. Regarding current trading prices, EXEL is priced at $50.45, while TGTX trades at $37.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas TGTX's P/E ratio is 13.27. In terms of profitability, EXEL's ROE is +0.40%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, EXEL is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check TGTX's competition here
EXEL vs CDTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, EXEL is priced at $50.45, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CDTX's P/E ratio is -19.77. In terms of profitability, EXEL's ROE is +0.40%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, EXEL is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check CDTX's competition here
EXEL vs ABCM Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $50.45, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, EXEL's ROE is +0.40%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, EXEL is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check ABCM's competition here
EXEL vs ISEE Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $50.45, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ISEE's P/E ratio is -22.44. In terms of profitability, EXEL's ROE is +0.40%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, EXEL is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check ISEE's competition here
EXEL vs CGON Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $50.45, while CGON trades at $59.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CGON's P/E ratio is -26.62. In terms of profitability, EXEL's ROE is +0.40%, compared to CGON's ROE of -0.23%. Regarding short-term risk, EXEL is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check CGON's competition here
EXEL vs LQDA Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, LQDA has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $50.45, while LQDA trades at $59.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas LQDA's P/E ratio is 362.94. In terms of profitability, EXEL's ROE is +0.40%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, EXEL is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check LQDA's competition here
EXEL vs CRSP Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, EXEL is priced at $50.45, while CRSP trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CRSP's P/E ratio is -9.11. In terms of profitability, EXEL's ROE is +0.40%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, EXEL is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check CRSP's competition here
EXEL vs APLS Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, EXEL is priced at $50.45, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas APLS's P/E ratio is 38.35. In terms of profitability, EXEL's ROE is +0.40%, compared to APLS's ROE of +0.40%. Regarding short-term risk, EXEL is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check APLS's competition here
EXEL vs FBIOX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, EXEL is priced at $50.45, while FBIOX trades at $25.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas FBIOX's P/E ratio is N/A. In terms of profitability, EXEL's ROE is +0.40%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, EXEL is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check FBIOX's competition here
EXEL vs MIRM Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, EXEL is priced at $50.45, while MIRM trades at $95.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas MIRM's P/E ratio is -7.46. In terms of profitability, EXEL's ROE is +0.40%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, EXEL is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check MIRM's competition here
EXEL vs APGE Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, APGE has a market cap of 5.1B. Regarding current trading prices, EXEL is priced at $50.45, while APGE trades at $80.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas APGE's P/E ratio is -18.97. In terms of profitability, EXEL's ROE is +0.40%, compared to APGE's ROE of -0.33%. Regarding short-term risk, EXEL is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check APGE's competition here
EXEL vs LEGN Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, LEGN has a market cap of 5B. Regarding current trading prices, EXEL is priced at $50.45, while LEGN trades at $25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas LEGN's P/E ratio is -19.68. In terms of profitability, EXEL's ROE is +0.40%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, EXEL is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check LEGN's competition here
EXEL vs TERN Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, EXEL is priced at $50.45, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas TERN's P/E ratio is -51.41. In terms of profitability, EXEL's ROE is +0.40%, compared to TERN's ROE of -0.20%. Regarding short-term risk, EXEL is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check TERN's competition here
EXEL vs CAI Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CAI has a market cap of 4.7B. Regarding current trading prices, EXEL is priced at $50.45, while CAI trades at $16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CAI's P/E ratio is -6.06. In terms of profitability, EXEL's ROE is +0.40%, compared to CAI's ROE of +0.06%. Regarding short-term risk, EXEL is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check CAI's competition here
EXEL vs LGND Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, LGND has a market cap of 4.6B. Regarding current trading prices, EXEL is priced at $50.45, while LGND trades at $230.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas LGND's P/E ratio is 30.24. In terms of profitability, EXEL's ROE is +0.40%, compared to LGND's ROE of +0.16%. Regarding short-term risk, EXEL is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check LGND's competition here
EXEL vs FOLD Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $50.45, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas FOLD's P/E ratio is -161.00. In terms of profitability, EXEL's ROE is +0.40%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, EXEL is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check FOLD's competition here
EXEL vs AKRO Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $50.45, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas AKRO's P/E ratio is -14.57. In terms of profitability, EXEL's ROE is +0.40%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check AKRO's competition here
EXEL vs ALPN Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $50.45, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ALPN's P/E ratio is -101.52. In terms of profitability, EXEL's ROE is +0.40%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, EXEL is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check ALPN's competition here
EXEL vs SYRE Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, SYRE has a market cap of 4.4B. Regarding current trading prices, EXEL is priced at $50.45, while SYRE trades at $70.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas SYRE's P/E ratio is -34.67. In terms of profitability, EXEL's ROE is +0.40%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, EXEL is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check SYRE's competition here
EXEL vs TVTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, TVTX has a market cap of 4.4B. Regarding current trading prices, EXEL is priced at $50.45, while TVTX trades at $45.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas TVTX's P/E ratio is -94.36. In terms of profitability, EXEL's ROE is +0.40%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, EXEL is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check TVTX's competition here
EXEL vs XENE Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, XENE has a market cap of 4.3B. Regarding current trading prices, EXEL is priced at $50.45, while XENE trades at $53.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas XENE's P/E ratio is -11.64. In terms of profitability, EXEL's ROE is +0.40%, compared to XENE's ROE of -0.49%. Regarding short-term risk, EXEL is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check XENE's competition here
EXEL vs OPT Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, EXEL is priced at $50.45, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas OPT's P/E ratio is -1.52. In terms of profitability, EXEL's ROE is +0.40%, compared to OPT's ROE of +0.88%. Regarding short-term risk, EXEL is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check OPT's competition here
EXEL vs MANE Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, MANE has a market cap of 4.2B. Regarding current trading prices, EXEL is priced at $50.45, while MANE trades at $102.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas MANE's P/E ratio is -38.26. In terms of profitability, EXEL's ROE is +0.40%, compared to MANE's ROE of -0.95%. Regarding short-term risk, EXEL is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check MANE's competition here
EXEL vs MRTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, EXEL is priced at $50.45, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas MRTX's P/E ratio is -4.82. In terms of profitability, EXEL's ROE is +0.40%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, EXEL is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check MRTX's competition here
EXEL vs ERAS Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ERAS has a market cap of 4B. Regarding current trading prices, EXEL is priced at $50.45, while ERAS trades at $14.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ERAS's P/E ratio is -13.81. In terms of profitability, EXEL's ROE is +0.40%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, EXEL is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check ERAS's competition here
EXEL vs NAMS Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, EXEL is priced at $50.45, while NAMS trades at $32.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas NAMS's P/E ratio is -18.92. In terms of profitability, EXEL's ROE is +0.40%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, EXEL is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check NAMS's competition here
EXEL vs DNTH Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, DNTH has a market cap of 3.9B. Regarding current trading prices, EXEL is priced at $50.45, while DNTH trades at $90.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas DNTH's P/E ratio is -21.99. In terms of profitability, EXEL's ROE is +0.40%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, EXEL is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check DNTH's competition here
EXEL vs CPRX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, EXEL is priced at $50.45, while CPRX trades at $31.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CPRX's P/E ratio is 18.05. In terms of profitability, EXEL's ROE is +0.40%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, EXEL is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check CPRX's competition here
EXEL vs VKTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, EXEL is priced at $50.45, while VKTX trades at $31.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas VKTX's P/E ratio is -7.89. In terms of profitability, EXEL's ROE is +0.40%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, EXEL is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check VKTX's competition here
EXEL vs RYZB Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, EXEL is priced at $50.45, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas RYZB's P/E ratio is -57.86. In terms of profitability, EXEL's ROE is +0.40%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, EXEL is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check RYZB's competition here
EXEL vs CRNX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $50.45, while CRNX trades at $34.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CRNX's P/E ratio is -6.92. In terms of profitability, EXEL's ROE is +0.40%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, EXEL is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check CRNX's competition here
EXEL vs CBAY Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $50.45, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas CBAY's P/E ratio is -32.81. In terms of profitability, EXEL's ROE is +0.40%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, EXEL is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check CBAY's competition here
EXEL vs ACAD Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $50.45, while ACAD trades at $21.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas ACAD's P/E ratio is 9.80. In terms of profitability, EXEL's ROE is +0.40%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, EXEL is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check ACAD's competition here
EXEL vs VCYT Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $50.45, while VCYT trades at $48.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas VCYT's P/E ratio is 42.91. In terms of profitability, EXEL's ROE is +0.40%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, EXEL is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check VCYT's competition here
EXEL vs EWTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $50.45, while EWTX trades at $39.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas EWTX's P/E ratio is -20.58. In terms of profitability, EXEL's ROE is +0.40%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, EXEL is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check EWTX's competition here
EXEL vs KNSA Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, KNSA has a market cap of 3.6B. Regarding current trading prices, EXEL is priced at $50.45, while KNSA trades at $48.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas KNSA's P/E ratio is 53.16. In terms of profitability, EXEL's ROE is +0.40%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, EXEL is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check KNSA's competition here
EXEL vs SWTX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, EXEL is priced at $50.45, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas SWTX's P/E ratio is -13.78. In terms of profitability, EXEL's ROE is +0.40%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, EXEL is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check SWTX's competition here
EXEL vs BEAM Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, BEAM has a market cap of 3.4B. Regarding current trading prices, EXEL is priced at $50.45, while BEAM trades at $31.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas BEAM's P/E ratio is -67.20. In terms of profitability, EXEL's ROE is +0.40%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, EXEL is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check BEAM's competition here
EXEL vs DNLI Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, EXEL is priced at $50.45, while DNLI trades at $20.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas DNLI's P/E ratio is -7.30. In terms of profitability, EXEL's ROE is +0.40%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, EXEL is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for EXEL.Check DNLI's competition here
EXEL vs TLX Comparison June 2026
EXEL plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EXEL stands at 12.7B. In comparison, TLX has a market cap of 3.2B. Regarding current trading prices, EXEL is priced at $50.45, while TLX trades at $9.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EXEL currently has a P/E ratio of 16.72, whereas TLX's P/E ratio is -471.50. In terms of profitability, EXEL's ROE is +0.40%, compared to TLX's ROE of -0.02%. Regarding short-term risk, EXEL is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for EXEL.Check TLX's competition here